More biotech and health care stories
Two No Surprises Act arbitrators lose government contracts to decide payment disputes
The groups, Island Peer Review Organization, or IPRO, and Network Medical Review Company, will no longer be able to accept new disputes, the government said.
Pharma critic Bernie Sanders is set to hold major sway over FDA funding bill
The FDA collects user fees from pharmaceutical companies to fund the agency’s reviews of their medicines. The Prescription User Fee Drug Act must be renewed before the current law expires on Sept. 30. Otherwise, it could disrupt the FDA’s ability to approve medicines.
WICKED EXPEN$IVE
How this ‘Love Is Blind’ contestant, a biotech engineer, spends her six-figure salary
Aneha Singh talked about paying close to $3,000 a month on rent in Cambridge, her splurges on fashion and makeup, and what it means to be a "traditional modern woman."
‘Kind of heartbreaking’: Mass General Brigham to close its only primary care clinic in Downtown Crossing
The scheduled closure is unrelated to MGB's efforts to cut costs, a spokesperson said.
We invited three psychologists to watch ‘You Can See Everything,’ and this is what they had to say
The Globe arranged a screening of the film “You Can See Everything” with three psychologists to get their interpretations of the head-spinning events depicted.
CVS Health to split, reversing years of deal-making to combine pharmacies and insurance
The decision to break up Woonsocket, R.I.-based CVS, which has more than $400 billion of annual revenue, stunned Wall Street.
Massachusetts patient pricing transparency law tangled in red tape
A 2021 health care pricing transparency law intended to alert patients about the cost of procedures and whether providers are in network has yet to take effect, and pending legislation could delay implementation again by another two years.
Watertown biotech’s coming eczema trial results could lead to a blockbuster — or bust
Kymera Therapeutics plans to announce data from a mid-stage clinical trial of its lead asset, KT-621, in eczema before the end of the year.